Company overview
Ncardia specializes in iPSC technology, offering high-quality stem cell derivation, differentiation, and manufacturing for cardiac and neuronal applications in drug discovery. They provide custom disease models, assay development, and screening services using human iPSC-derived cells to enhance efficacy and safety assessments across small molecules, biologics, cell, gene, and RNA therapies. Their solutions support early-stage pipelines with scalable, automated assays that improve translational relevance over animal models.
Ncardia is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include ipsc technology, disease modeling, drug screening, cardiac assays, stem cell services.
Products and technologies associated with Ncardia include Assay — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.ncardia.com
- Markets served
- United States & Americas
- Keywords
- ipsc technology, disease modeling, drug screening, cardiac assays, stem cell services
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What iPSC services does Ncardia offer for pharma R&D?
- Ncardia provides iPSC generation, at-scale differentiation, cell manufacturing, disease modeling, assay development, and custom screening for cardiac and neuronal applications in drug discovery pipelines.
- What therapeutic modalities do Ncardia's assays support?
- Assays support small molecules, biologics, cell, gene, and RNA therapies, delivering clinically relevant data on efficacy and safety using human iPSC-derived models.
- What assay capabilities does Ncardia have for cardiac safety?
- Capabilities include multielectrode array (MEA) analysis for electrophysiological profiling in iPSC-derived cardiomyocytes, plus automated cardiac microtissue platforms for high-throughput screening.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
